Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge

David T. Huang(University of Pittsburgh), Christopher Seymour(University of Pittsburgh), Daniel Ricketts(University of Pittsburgh), Richard J. Wadas(University of Pittsburgh), Anna Nakayama, Graham M. Snyder(University of Pittsburgh), Oscar C. Marroquin(University of Pittsburgh), Scott Berry(Queen's University), Octavia M. Peck‐Palmer(University of Pittsburgh), Rachel L. Zapf(University of Pittsburgh Medical Center), Amy Crawford(Berry & Associates (United States)), Russell Meyers(University of Pittsburgh), Anne Yang(University of Pittsburgh), Erin K McCreary(University of Pittsburgh Medical Center), Jason Kennedy(University of Pittsburgh), Alexandra Weissman(University of Pittsburgh), Kevin E. Kip(UPMC Health System), Meredith Axe(University of Pittsburgh), Ghady Haidar(University of Pittsburgh Medical Center), Paula L. Kip(University of Pittsburgh Medical Center), Caroline Pidro(University of Pittsburgh), Tina Khadem(University of Pittsburgh Medical Center), Bryan J. McVerry(University of Pittsburgh), Tami Minnier(University of Pittsburgh Medical Center), Judith A. Shovel(University of Pittsburgh Medical Center), William Garrard(UPMC Health System), J Ryan Bariola(University of Pittsburgh), Debbie Albin(UPMC Health System), Anna McGlothlin(Berry & Associates (United States)), Alan Wells(University of Pittsburgh), Mary Kay Wisniewski(University of Pittsburgh Medical Center), Mark Schmidhofer(University of Pittsburgh), Robert D. Bart(UPMC Health System), Lindsay R. Berry(Berry & Associates (United States)), Stephanie K. Montgomery(University of Pittsburgh), Kelsey Linstrum(University of Pittsburgh), Donald M. Yealy(University of Pittsburgh), Colleen Sullivan(University of Pittsburgh), David A. Nace(University of Pittsburgh), Kevin Collins(UPMC Health System), Derek C. Angus(University of Pittsburgh)
JAMA Network Open
July 14, 2022
Cited by 54


Related Papers